Mdr 745 Specialist

MDR 2017/745 Specialist

EU MDR compliance patterns for medical device classification, technical documentation, and clinical evidence.

---

Table of Contents

• Device Classification Workflow
• Technical Documentation
• Clinical Evidence
• Post-Market Surveillance
• EUDAMED and UDI
• Reference Documentation
• Tools

---

Device Classification Workflow

Classify device under MDR Annex VIII:

1. Identify device duration (transient, short-term, long-term) 2. Determine invasiveness level (non-invasive, body orifice, surgical) 3. Assess body system contact (CNS, cardiac, other) 4. Check if active device (energy dependent) 5. Apply classification rules 1-22 6. For software, apply MDCG 2019-11 algorithm 7. Document classification rationale 8. Validation: Classification confirmed with Notified Body

Classification Matrix

Software Classification (MDCG 2019-11)

Classification Examples

Example 1: Absorbable Surgical Suture

• Rule 8 (implantable, long-term)
• Duration: > 30 days (absorbed)
• Contact: General tissue
• Classification: Class IIb

Example 2: AI Diagnostic Software

• Rule 11 + MDCG 2019-11
• Function: Diagnoses serious condition
• Classification: Class IIb

Example 3: Cardiac Pacemaker

• Rule 8 (implantable)
• Contact: Central circulatory system
• Classification: Class III

---

Technical Documentation

Prepare technical file per Annex II and III:

1. Create device description (variants, accessories, intended purpose) 2. Develop labeling (Article 13 requirements, IFU) 3. Document design and manufacturing process 4. Complete GSPR compliance matrix 5. Prepare benefit-risk analysis 6. Compile verification and validation evidence 7. Integrate risk management file (ISO 14971) 8. Validation: Technical file reviewed for completeness

Technical File Structure

ANNEX II TECHNICAL DOCUMENTATION
├── Device description and UDI-DI
├── Label and instructions for use
├── Design and manufacturing info
├── GSPR compliance matrix
├── Benefit-risk analysis
├── Verification and validation
└── Clinical evaluation report

GSPR Compliance Checklist

Conformity Assessment Routes

---

Clinical Evidence

Develop clinical evidence strategy per Annex XIV:

1. Define clinical claims and endpoints 2. Conduct systematic literature search 3. Appraise clinical data quality 4. Assess equivalence (technical, biological, clinical) 5. Identify evidence gaps 6. Determine if clinical investigation required 7. Prepare Clinical Evaluation Report (CER) 8. Validation: CER reviewed by qualified evaluator

Evidence Requirements by Class

Clinical Evaluation Report Structure

CER CONTENTS
├── Executive summary
├── Device scope and intended purpose
├── Clinical background (state of the art)
├── Literature search methodology
├── Data appraisal and analysis
├── Safety and performance conclusions
├── Benefit-risk determination
└── PMCF plan summary

Qualified Evaluator Requirements

• Medical degree or equivalent healthcare qualification
• 4+ years clinical experience in relevant field
• Training in clinical evaluation methodology
• Understanding of MDR requirements

---

Post-Market Surveillance

Establish PMS system per Chapter VII:

1. Develop PMS plan (Article 84) 2. Define data collection methods 3. Establish complaint handling procedures 4. Create vigilance reporting process 5. Plan Periodic Safety Update Reports (PSUR) 6. Integrate with PMCF activities 7. Define trend analysis and signal detection 8. Validation: PMS system audited annually

PMS System Components

PSUR Schedule

Serious Incident Reporting

---

EUDAMED and UDI

Implement UDI system per Article 27:

1. Obtain issuing entity code (GS1, HIBCC, ICCBBA) 2. Assign UDI-DI to each device variant 3. Assign UDI-PI (production identifier) 4. Apply UDI carrier to labels (AIDC + HRI) 5. Register actor in EUDAMED 6. Register devices in EUDAMED 7. Upload certificates when available 8. Validation: UDI verified on sample labels

EUDAMED Modules

UDI Label Requirements

Required elements per Article 13:

• [ ] UDI-DI (device identifier)
• [ ] UDI-PI (production identifier) for Class II+
• [ ] AIDC format (barcode/RFID)
• [ ] HRI format (human-readable)
• [ ] Manufacturer name and address
• [ ] Lot/serial number
• [ ] Expiration date (if applicable)

---

Reference Documentation

MDR Classification Guide

references/mdr-classification-guide.md contains:

• Complete Annex VIII classification rules (Rules 1-22)
• Software classification per MDCG 2019-11
• Worked classification examples
• Conformity assessment route selection

Clinical Evidence Requirements

references/clinical-evidence-requirements.md contains:

• Clinical evidence framework and hierarchy
• Literature search methodology
• Clinical Evaluation Report structure
• PMCF plan and evaluation report guidance

Technical Documentation Templates

references/technical-documentation-templates.md contains:

• Annex II and III content requirements
• Design History File structure
• GSPR compliance matrix template
• Declaration of Conformity template
• Notified Body submission checklist

---

Tools

MDR Gap Analyzer

# Quick gap analysis
python scripts/mdr_gap_analyzer.py --device "Device Name" --class IIa

# JSON output for integration
python scripts/mdr_gap_analyzer.py --device "Device Name" --class III --output json

# Interactive assessment
python scripts/mdr_gap_analyzer.py --interactive

Analyzes device against MDR requirements, identifies compliance gaps, generates prioritized recommendations.

Output includes:

• Requirements checklist by category
• Gap identification with priorities
• Critical gap highlighting
• Compliance roadmap recommendations

---

Notified Body Interface

Selection Criteria

Pre-Submission Checklist

• [ ] Technical documentation complete
• [ ] GSPR matrix fully addressed
• [ ] Risk management file current
• [ ] Clinical evaluation report complete
• [ ] QMS (ISO 13485) certified
• [ ] Labeling and IFU finalized
• [ ] Validation: Internal gap assessment complete

Clinical Evidence Requirements

MDR Annex XIV clinical evaluation and post-market clinical follow-up guidance.

---

Table of Contents

• Clinical Evidence Framework
• Clinical Evaluation Process
• Literature-Based Evidence
• Clinical Investigation Requirements
• Post-Market Clinical Follow-up

---

Clinical Evidence Framework

Evidence Hierarchy

Evidence Requirements by Class

Clinical Evidence Pathway

Determine evidence strategy:

1. Assess device classification and risk level 2. Evaluate claim significance (diagnostic, therapeutic) 3. Determine if equivalence can be demonstrated 4. Identify available literature and clinical data 5. Assess gaps requiring additional investigation 6. Develop PMCF plan for ongoing evidence 7. Validation: Evidence strategy approved by Notified Body

---

Clinical Evaluation Process

Clinical Evaluation Workflow

Execute clinical evaluation per Annex XIV Part A:

1. Identify relevant safety and performance data 2. Define scope and search strategy 3. Conduct systematic literature search 4. Appraise and analyze clinical data 5. Assess benefit-risk profile 6. Document conclusions in Clinical Evaluation Report (CER) 7. Plan post-market clinical follow-up 8. Validation: CER reviewed by qualified clinical evaluator

Clinical Evaluation Report Structure

CLINICAL EVALUATION REPORT (CER)
├── 1. Executive Summary
│   ├── Device description and intended purpose
│   ├── Conclusions on safety and performance
│   └── Benefit-risk conclusion
├── 2. Scope of Clinical Evaluation
│   ├── Device identification
│   ├── Clinical claims to be evaluated
│   └── Equivalence assessment (if applicable)
├── 3. Clinical Background
│   ├── Disease/condition overview
│   ├── Current treatment options
│   └── State of the art
├── 4. Clinical Data Sources
│   ├── Pre-clinical data (bench, animal)
│   ├── Clinical investigation data
│   ├── Literature search methodology
│   └── Post-market surveillance data
├── 5. Data Appraisal
│   ├── Study quality assessment
│   ├── Relevance to subject device
│   └── Data contribution to evaluation
├── 6. Data Analysis
│   ├── Safety analysis
│   ├── Performance analysis
│   └── Benefit-risk determination
├── 7. Conclusions
│   ├── Clinical evidence summary
│   ├── Residual risks
│   └── PMCF requirements
└── 8. PMCF Plan Summary
    ├── Data gaps identified
    ├── PMCF activities planned
    └── Update schedule

Qualified Clinical Evaluator

Requirements per Annex XIV:

• Medical degree or equivalent healthcare qualification
• 4+ years clinical experience in relevant field OR
• Research background in relevant domain
• Training in clinical evaluation methodology
• Understanding of MDR requirements

---

Literature-Based Evidence

Literature Search Strategy

Execute systematic literature review:

1. Define PICO question (Population, Intervention, Comparison, Outcome) 2. Develop search string with Boolean operators 3. Select databases (PubMed, Embase, Cochrane, etc.) 4. Set date range and language filters 5. Execute search and document results 6. Screen abstracts and full texts 7. Validation: Reproducible search, documented exclusion criteria

Database Selection

Data Appraisal Criteria

Evaluate each source:

Equivalence Assessment

Demonstrate equivalence per MDCG 2020-5:

Technical equivalence:

• Similar design
• Same materials
• Same specifications
• Same manufacturing process

Biological equivalence:

• Same tissue contact
• Same biocompatibility
• Same sterilization method

Clinical equivalence:

• Same intended purpose
• Same clinical condition
• Same patient population
• Same user (professional/lay)

---

Clinical Investigation Requirements

When Investigation is Required

Clinical investigation mandatory:

• [ ] Class III implantable devices (Article 61(4))
• [ ] Novel technology without equivalent
• [ ] Significant modification to existing device
• [ ] New clinical claims not supported by literature
• [ ] Addressing gaps identified in clinical evaluation

Clinical Investigation Workflow

Conduct clinical investigation:

1. Develop Clinical Investigation Plan (CIP) 2. Submit to Ethics Committee for approval 3. Notify Competent Authority (via EUDAMED) 4. Conduct investigation per GCP principles 5. Collect and analyze clinical data 6. Prepare Clinical Investigation Report 7. Submit serious adverse event reports (within 7-15 days) 8. Validation: All subjects completed, data lock achieved

Clinical Investigation Plan Elements

Ethics Committee Submission

Required documentation:

• Clinical Investigation Plan
• Investigator's Brochure
• Informed consent documents
• Case Report Forms
• Investigator CVs
• Insurance certificate
• Device documentation

---

Post-Market Clinical Follow-up

PMCF Plan Requirements

Develop PMCF Plan per Annex XIV Part B:

1. Identify residual risks from clinical evaluation 2. Define clinical questions to address 3. Select PMCF methods (survey, registry, study) 4. Specify endpoints and success criteria 5. Define timeline and milestones 6. Plan data collection and analysis 7. Schedule PMCF Evaluation Report updates 8. Validation: PMCF Plan approved by Notified Body

PMCF Methods

PMCF Evaluation Report

Update frequency:

PMCF Report Structure

PMCF EVALUATION REPORT
├── 1. Executive Summary
│   └── Key findings and conclusions
├── 2. Scope
│   ├── Device covered
│   └── Reporting period
├── 3. PMCF Activities
│   ├── Methods employed
│   └── Data sources
├── 4. Results
│   ├── Safety data
│   ├── Performance data
│   └── Clinical questions addressed
├── 5. Conclusions
│   ├── Benefit-risk confirmation
│   ├── Residual risks updated
│   └── Need for corrective action
└── 6. Next Steps
    ├── CER update requirements
    └── PMCF Plan modifications

Integration with CER

PMCF data feeds clinical evaluation:

1. PMCF data collected per plan 2. Data analyzed in PMCF Evaluation Report 3. CER updated with PMCF conclusions 4. Risk management file updated 5. IFU updated if needed 6. Validation: CER update cycle completed

MDR Device Classification Guide

EU MDR 2017/745 Annex VIII classification rules and decision framework.

---

Table of Contents

• Classification Overview
• Classification Rules
• Software Classification (MDCG 2019-11)
• Classification Examples
• Conformity Assessment Routes

---

Classification Overview

Risk Class Hierarchy

Classification Factors

Determine class based on:

1. Duration of contact:

• Transient: < 60 minutes
• Short-term: 60 min to 30 days
• Long-term: > 30 days

2. Degree of invasiveness:

• Non-invasive
• Invasive via body orifice
• Surgically invasive
• Implantable

3. Body system interaction:

• Central circulatory system
• Central nervous system
• Other organ systems

4. Active vs. passive:

• Active devices (energy dependent)
• Passive devices

---

Classification Rules

Non-Invasive Devices (Rules 1-4)

Rule 1 - General non-invasive:

• Class I (unless covered by other rules)
• Example: Wheelchairs, hospital beds, collection devices

Rule 2 - Channeling or storing:

• Class IIa: Blood bags, transfusion sets (>60 min contact)
• Class IIb: Blood storage, organ storage
• Class I: Simple channeling (gravity, IV bag without additives)

Rule 3 - Modifying biological composition:

• Class IIa: Filters, gas separators, dialysis filters
• Class IIb: Blood filtration, exchange transfusion

Rule 4 - Contact with injured skin:

• Class I: Wound dressings for superficial wounds
• Class IIa: Wounds in dermis requiring secondary intent healing
• Class IIb: Severe wounds, chronic wounds, burns

Invasive Devices (Rules 5-8)

Rule 5 - Body orifice invasive (transient):

• Class I: Transient use, non-surgically invasive
• Class IIa: Short-term use
• Class IIb: Long-term use in oral cavity

Rule 6 - Surgically invasive (transient):

• Class IIa: Transient use
• Exception Class I: Reusable surgical instruments

Rule 7 - Surgically invasive (short-term):

• Class IIa: Short-term (< 30 days)
• Class IIb: Central circulatory or CNS contact
• Class III: Chemical change or drug delivery

Rule 8 - Implantable and long-term surgically invasive:

• Class IIb: General implants
• Class III: Heart, CNS, spine contact; drug delivery; biological origin

Active Devices (Rules 9-13)

Rule 9 - Active therapeutic devices:

• Class IIa: Exchange or admin of energy (non-hazardous)
• Class IIb: Potentially hazardous energy levels

Rule 10 - Active diagnostic devices:

• Class IIa: Supply energy for imaging, monitoring
• Class IIb: Monitor vital physiological parameters

Rule 11 - Software:

• Class IIa: Information for diagnostic/therapeutic decisions (non-serious)
• Class IIb: Decisions that could cause death/irreversible deterioration
• Class III: Decisions with immediate risk to life
• See MDCG 2019-11 for detailed algorithm

Rule 12 - Active devices administering substances:

• Class IIa: Non-hazardous manner
• Class IIb: Potentially hazardous manner

Rule 13 - Other active devices:

• Class I: All other active devices

Special Rules (Rules 14-22)

Rule 14 - Contraception/STI prevention:

• Class IIb: Contraceptive devices
• Class III: Implantable contraceptives

Rule 15 - Disinfection/sterilization:

• Class IIa: Disinfection of devices
• Class IIb: Disinfection of invasive devices

Rule 16 - X-ray diagnostic recording:

• Class IIa: Recording media for x-ray

Rule 17 - Devices with nanomaterials:

• Class III: High internal exposure potential
• Class IIb: Medium exposure
• Class IIa: Low exposure

Rule 18 - Blood/plasma derivatives:

• Class III: Utilizing blood derivatives

Rule 19 - Drug delivery systems:

• Class III: Integral drug administration

Rule 20 - Breath analyzers for anesthesia:

• Class IIb: Breath analyzers

Rule 21 - Medicinal substance devices:

• Class III: Incorporating medicinal substances

Rule 22 - Closed-loop therapeutic systems:

• Class III: Closed-loop systems

---

Software Classification

MDCG 2019-11 Decision Algorithm

Execute software classification:

1. Determine if software qualifies as medical device 2. Identify significance of information to healthcare decision 3. Assess healthcare situation or patient condition 4. Apply rule 11 based on severity 5. Validation: Classification rationale documented with MDCG reference

Software Classification Matrix

Software Examples

---

Classification Examples

Example 1: Surgical Suture (Absorbable)

Device: Absorbable suture for internal wound closure
Analysis:
- Invasiveness: Surgically invasive
- Duration: Long-term (absorbed over > 30 days)
- System: General tissue (not CNS, not cardiac)
- Rule Applied: Rule 8 (implantable, long-term)

Classification: Class IIb
Rationale: Implantable device > 30 days, general tissue
Conformity Route: Annex IX (Type examination) + Annex XI

Example 2: Blood Pressure Monitor

Device: Home blood pressure monitoring device
Analysis:
- Active: Yes (electronic measurement)
- Function: Monitoring vital physiological parameter
- Risk: Non-immediate (home use, not ICU)
- Rule Applied: Rule 10 (active diagnostic)

Classification: Class IIa
Rationale: Monitors vital parameter, non-critical setting
Conformity Route: Annex IX or XI (QMS + product verification)

Example 3: Hip Implant

Device: Total hip replacement prosthesis
Analysis:
- Invasiveness: Surgically invasive, implantable
- Duration: Long-term (permanent)
- System: Musculoskeletal
- Rule Applied: Rule 8 (implantable, long-term)

Classification: Class III
Rationale: Implantable > 30 days in direct contact with bone
Conformity Route: Annex IX + Annex X (full QMS + type examination)

Example 4: Diagnostic Software (AI)

Device: AI-based chest X-ray analysis for pneumonia detection
Analysis:
- Software: Qualifies as medical device (clinical decision)
- Information: Diagnoses condition
- Condition: Serious (pneumonia can be life-threatening)
- Rule Applied: Rule 11 + MDCG 2019-11

Classification: Class IIb
Rationale: Software diagnosing serious condition
Conformity Route: Annex IX or Annex XI

---

Conformity Assessment Routes

By Device Class

Annex Reference

Decision Workflow

Select conformity route:

1. Determine device classification (Rules 1-22) 2. Identify applicable annexes for class 3. Evaluate QMS maturity (Annex IX capability) 4. Consider production volume (batch vs. mass) 5. Assess Notified Body capacity and timeline 6. Select optimal conformity assessment route 7. Validation: Route confirmed with Notified Body consultation

Technical Documentation Templates

MDR Annex II and III technical file structure and content requirements.

---

Table of Contents

• Technical Documentation Overview
• Annex II Requirements
• Annex III Additions
• Document Templates
• Notified Body Expectations

---

Technical Documentation Overview

Documentation Hierarchy

TECHNICAL DOCUMENTATION
├── Device Description and Specification
├── Information Supplied by Manufacturer
├── Design and Manufacturing Information
├── General Safety and Performance Requirements
├── Benefit-Risk Analysis
├── Product Verification and Validation
├── Clinical Evaluation Report
└── Post-Market Surveillance Documentation

Documentation by Phase

---

Annex II Requirements

Section 1: Device Description and Specification

1.1 Device Identification

DEVICE IDENTIFICATION
├── Trade name(s)
├── General description of the device
├── Basic UDI-DI
├── Device identifier codes (internal + regulatory)
├── Intended purpose statement
├── Indications for use
├── Contraindications
├── Target population (patient, user)
├── Medical conditions intended to diagnose/treat
└── Principles of operation

1.2 Device Variants and Accessories

1.3 Reference to Previous Generations

• Previous generation device identification
• Key modifications summary
• Clinical experience from prior device
• Justification for changes

Section 2: Information Supplied by Manufacturer

2.1 Label Requirements

Mandatory label elements per Article 13:

• [ ] Device name or trade name
• [ ] Manufacturer name and address
• [ ] Authorized representative (if applicable)
• [ ] Lot/batch number or serial number
• [ ] UDI carrier (AIDC + HRI)
• [ ] Expiration date (if applicable)
• [ ] Storage/handling conditions
• [ ] Warnings and precautions
• [ ] CE mark with NB number (if applicable)
• [ ] Symbol meanings per EN ISO 15223-1

2.2 Instructions for Use

IFU structure:

INSTRUCTIONS FOR USE
├── 1. Device Description
│   ├── Intended purpose
│   ├── Indications and contraindications
│   └── Principle of operation
├── 2. Warnings and Precautions
│   ├── Contraindicated uses
│   ├── Potential complications
│   └── Drug/device interactions
├── 3. User Instructions
│   ├── Unpacking and inspection
│   ├── Setup/installation
│   ├── Operating procedures
│   └── Cleaning/maintenance
├── 4. Technical Specifications
│   ├── Physical characteristics
│   ├── Performance characteristics
│   └── Environmental limits
├── 5. Troubleshooting
│   ├── Error codes/messages
│   └── Corrective actions
└── 6. Symbols Glossary

Section 3: Design and Manufacturing Information

3.1 Design Process Documentation

3.2 Manufacturing Process Description

MANUFACTURING DOCUMENTATION
├── Process flow diagram
├── Manufacturing specifications
├── Facility and equipment qualification
├── Process validation protocols/reports
├── Environmental monitoring
├── Personnel training records
├── In-process controls
├── Final inspection/testing
├── Sterilization validation (if applicable)
└── Packaging validation

3.3 Supplier and Subcontractor Information

• Approved supplier list
• Supplier qualification records
• Critical component specifications
• Incoming inspection procedures
• Supplier audit records

Section 4: General Safety and Performance Requirements

GSPR Compliance Checklist

GSPR Matrix Template

Section 5: Benefit-Risk Analysis

Benefit-Risk Documentation

BENEFIT-RISK ANALYSIS
├── 1. Intended Benefits
│   ├── Direct therapeutic benefits
│   ├── Diagnostic accuracy improvements
│   └── Patient outcome benefits
├── 2. Known Risks
│   ├── Identified hazards (from risk analysis)
│   ├── Risk control measures implemented
│   └── Residual risks
├── 3. Benefit-Risk Determination
│   ├── Qualitative analysis
│   ├── Quantitative analysis (if available)
│   └── Comparison to alternatives
└── 4. Conclusion
    ├── Acceptability statement
    └── Justification for residual risks

Section 6: Product Verification and Validation

6.1 Verification Testing

6.2 Validation Evidence

• Clinical investigation data
• Literature-based clinical evidence
• Simulated use testing
• User feedback/complaint analysis
• Post-market surveillance data

---

Annex III Additions

Class III Specific Requirements

Additional documentation for Class III devices:

Implant-Specific Requirements

• Implant card information
• Patient information leaflet
• Device tracking procedures
• Explant analysis capability

Drug-Device Combination

• Drug substance specification
• Drug compatibility testing
• Combined product assessment
• Pharmacovigilance interface

---

Document Templates

Design History File Index

DESIGN HISTORY FILE (DHF)
Document ID: DHF-[Product]-[Rev]

1. DESIGN INPUT
   1.1 User Requirements Specification (URS)
   1.2 Regulatory Requirements Matrix
   1.3 Design Input Review Record

2. DESIGN OUTPUT
   2.1 Product Specification
   2.2 Engineering Drawings
   2.3 Bill of Materials
   2.4 Software Documentation

3. DESIGN VERIFICATION
   3.1 Verification Test Plan
   3.2 Verification Test Reports
   3.3 Traceability Matrix

4. DESIGN VALIDATION
   4.1 Clinical Evaluation Report
   4.2 Usability Engineering File
   4.3 Biocompatibility Evaluation

5. DESIGN TRANSFER
   5.1 Manufacturing Procedures
   5.2 Process Validation Reports
   5.3 Supplier Qualification

6. DESIGN REVIEWS
   6.1 Design Review Records
   6.2 Risk Management Review
   6.3 Final Design Release

Declaration of Conformity Template

EU DECLARATION OF CONFORMITY

We, [Manufacturer Name]
Address: [Full address]

declare under our sole responsibility that the device:

Device name: [Trade name]
Device description: [Description]
Basic UDI-DI: [UDI-DI]
Classification: [Class I/IIa/IIb/III]

is in conformity with the provisions of:
- Regulation (EU) 2017/745

Applicable standards:
- [List harmonized standards]

Notified Body: [NB name and number] (if applicable)
Certificate number: [Certificate number]

Place and date: [Location, Date]
Signature: [Authorized signatory]
Name and function: [Name, Title]

---

Notified Body Expectations

Common NB Findings

Pre-Submission Checklist

Before Notified Body submission:

• [ ] Technical documentation complete
• [ ] GSPR checklist fully addressed
• [ ] Risk management file current
• [ ] Clinical evaluation report complete
• [ ] QMS documentation ready
• [ ] Design verification complete
• [ ] Design validation complete
• [ ] Labeling and IFU finalized
• [ ] Declaration of conformity prepared
• [ ] Validation: Internal review completed